Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
QLS1128
DRUG
2 trials
Sponsors
Qilu Pharmaceutical Co., Ltd.
Conditions
COVID-19
Phase 2
A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
NCT05689203
Qilu Pharmaceutical Co., Ltd.
COVID-19
Start: 2022-12-30
End: 2023-02-01
Target: 360
Updated: 2023-01-19
Phase 3
A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19
NCT05758519
Qilu Pharmaceutical Co., Ltd.
COVID-19
Start: 2023-03-07
End: 2023-06-30
Target: 1220
Updated: 2023-03-10
Related Papers
Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review.
2025-01-01
1 citations